Krystal Biotech (NASDAQ:KRYS) EVP Sells $193,903.26 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Down 0.4%

Shares of Krystal Biotech stock opened at $309.03 on Friday. The stock’s 50-day simple moving average is $277.59 and its 200-day simple moving average is $260.77. Krystal Biotech, Inc. has a 52 week low of $123.03 and a 52 week high of $319.48. The company has a market capitalization of $9.11 billion, a price-to-earnings ratio of 41.31 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on KRYS shares. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Citigroup boosted their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Wall Street Zen upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Chardan Capital boosted their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. increased its stake in Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the last quarter. Sound Income Strategies LLC increased its stake in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares during the last quarter. Western Wealth Management LLC bought a new position in shares of Krystal Biotech during the first quarter valued at approximately $34,000. Greenline Wealth Management LLC bought a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $34,000. Finally, Danske Bank A S bought a new position in shares of Krystal Biotech during the third quarter valued at approximately $35,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.